Endocrine

, Volume 50, Issue 2, pp 297–305 | Cite as

PET imaging in ectopic Cushing syndrome: a systematic review

  • Prasanna Santhanam
  • David Taieb
  • Luca Giovanella
  • Giorgio Treglia
Review

Abstract

Cushing syndrome due to endogenous hypercortisolism may cause significant morbidity and mortality. The source of excess cortisol may be adrenal, pituitary, or ectopic. Ectopic Cushing syndrome is sometimes difficult to localize on conventional imaging like CT and MRI. After performing a multilevel thoracoabdominal imaging with CT, the evidence regarding the use of radiotracers for PET imaging is unclear due to significant molecular and etiological heterogeneity of potential causes of ectopic Cushing’s syndrome. In our systematic review of literature, it appears that GalLium-based (Ga68) somatostatin receptor analogs have better sensitivity in diagnosis of bronchial carcinoids causing Cushing syndrome and FDG PET appears superior for small-cell lung cancers and other aggressive tumors. Further large-scale studies are needed to identify the best PET tracer for this condition.

Keywords

PET Ectopic Cushing syndrome 18F-FDG Octreoscan 

References

  1. 1.
    H. Raff, Cushing syndrome: update on testing. Endocrinol. Metab. Clin. North Am. 44(1), 43–50 (2015). doi:10.1016/j.ecl.2014.10.005 CrossRefPubMedGoogle Scholar
  2. 2.
    Lynnette K Nieman, M.: Establishing the cause of Cushing’s syndrome. In: http://www.uptodate.com/contents/establishing-the-cause-of-cushings-syndrome?source=see_link. (Nov 26,2013)
  3. 3.
    E. Ur, A. Grossman, Corticotropin-releasing hormone in health and disease: an update. Acta Endocrinol. 127(3), 193–199 (1992)PubMedGoogle Scholar
  4. 4.
    J.D. Veldhuis, A. Iranmanesh, M.L. Johnson, G. Lizarralde, Amplitude, but not frequency, modulation of adrenocorticotropin secretory bursts gives rise to the nyctohemeral rhythm of the corticotropic axis in man. J. Clin. Endocrinol. Metab. 71(2), 452–463 (1990). doi:10.1210/jcem-71-2-452 CrossRefPubMedGoogle Scholar
  5. 5.
    E. Van Cauter, S. Refetoff, Evidence for two subtypes of Cushing’s disease based on the analysis of episodic cortisol secretion. N. Engl. J. Med. 312(21), 1343–1349 (1985). doi:10.1056/nejm198505233122102 CrossRefPubMedGoogle Scholar
  6. 6.
    E. Louiset, H. Lefebvre, Intraadrenal corticotropin in bilateral macronodular adrenal hyperplasia. N. Engl. J. Med. 370(11), 1071–1072 (2014). doi:10.1056/NEJMc1316140 CrossRefPubMedGoogle Scholar
  7. 7.
    E. Louiset, C. Duparc, J. Young, S. Renouf, M. Tetsi Nomigni, I. Boutelet, R. Libe, Z. Bram, L. Groussin, P. Caron, A. Tabarin, F. Grunenberger, S. Christin-Maitre, X. Bertagna, J.M. Kuhn, Y. Anouar, J. Bertherat, H. Lefebvre, Intraadrenal corticotropin in bilateral macronodular adrenal hyperplasia. N. Engl. J. Med. 369(22), 2115–2125 (2013). doi:10.1056/NEJMoa1215245 CrossRefPubMedGoogle Scholar
  8. 8.
    S. Ejaz, R. Vassilopoulou-Sellin, N.L. Busaidy, M.I. Hu, S.G. Waguespack, C. Jimenez, A.K. Ying, M. Cabanillas, M. Abbara, M.A. Habra, Cushing syndrome secondary to ectopic adrenocorticotropic hormone secretion: the University of Texas MD Anderson Cancer Center Experience. Cancer 117(19), 4381–4389 (2011). doi:10.1002/cncr.26029 PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    J.Y. Han, L. Mirsadraei, M.W. Yeh, J.D. Suh, W.H. Yong, M. Bergsneider, A.P. Heaney, Bilateral adrenalectomy: lifesaving procedure in severe Cushing syndrome. Endocr. Pract. 18(4), e85–e90 (2012). doi:10.4158/ep11315.cr CrossRefPubMedGoogle Scholar
  10. 10.
    A.M. Isidori, A. Lenzi, Ectopic ACTH syndrome. Arquivos brasileiros de endocrinologia e metabologia 51(8), 1217–1225 (2007)CrossRefPubMedGoogle Scholar
  11. 11.
    D. Ferone, M. Albertelli, Ectopic Cushing and other paraneoplastic syndromes in thoracic neuroendocrine tumors. Thorac. Surg. Clin. 24(3), 277–283 (2014). doi:10.1016/j.thorsurg.2014.05.002 CrossRefPubMedGoogle Scholar
  12. 12.
    J.P. Aniszewski, W.F. Young Jr, G.B. Thompson, C.S. Grant, J.A. van Heerden, Cushing syndrome due to ectopic adrenocorticotropic hormone secretion. World J. Surg. 25(7), 934–940 (2001)CrossRefPubMedGoogle Scholar
  13. 13.
    I. Ilias, D.J. Torpy, K. Pacak, N. Mullen, R.A. Wesley, L.K. Nieman, Cushing’s syndrome due to ectopic corticotropin secretion: twenty years’ experience at the National Institutes of Health. J. Clin. Endocrinol. Metab. 90(8), 4955–4962 (2005). doi:10.1210/jc.2004-2527 CrossRefPubMedGoogle Scholar
  14. 14.
    A.M. Isidori, G.A. Kaltsas, C. Pozza, V. Frajese, J. Newell-Price, R.H. Reznek, P.J. Jenkins, J.P. Monson, A.B. Grossman, G.M. Besser, The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up. J. Clin. Endocrinol. Metab. 91(2), 371–377 (2006). doi:10.1210/jc.2005-1542 CrossRefPubMedGoogle Scholar
  15. 15.
    G. Boddaert, B. Grand, F. Le Pimpec-Barthes, A. Cazes, X. Bertagna, M. Riquet, Bronchial carcinoid tumors causing Cushing’s syndrome: more aggressive behavior and the need for early diagnosis. Ann. Thorac. Surg. 94(6), 1823–1829 (2012). doi:10.1016/j.athoracsur.2012.07.022 CrossRefPubMedGoogle Scholar
  16. 16.
    K.I. Alexandraki, A.B. Grossman, The ectopic ACTH syndrome. Rev. Endocr. Metab. Disord. 11(2), 117–126 (2010). doi:10.1007/s11154-010-9139-z CrossRefPubMedGoogle Scholar
  17. 17.
    V. Rufini, M.L. Calcagni, R.P. Baum, Imaging of neuroendocrine tumors. Semin. Nucl. Med. 36(3), 228–247 (2006). doi:10.1053/j.semnuclmed.2006.03.007 CrossRefPubMedGoogle Scholar
  18. 18.
    W.W. de Herder, E.P. Krenning, C.D. Malchoff, L.J. Hofland, J.C. Reubi, D.J. Kwekkeboom, H.Y. Oei, H.A. Pols, H.A. Bruining, F.R. Nobels et al., Somatostatin receptor scintigraphy: its value in tumor localization in patients with Cushing’s syndrome caused by ectopic corticotropin or corticotropin-releasing hormone secretion. Am. J. Med. 96(4), 305–312 (1994)CrossRefPubMedGoogle Scholar
  19. 19.
    M. Phlipponneau, M. Nocaudie, J. Epelbaum, Y. De Keyzer, J.D. Lalau, X. Marchandise, X. Bertagna, Somatostatin analogs for the localization and preoperative treatment of an adrenocorticotropin-secreting bronchial carcinoid tumor. J. Clin. Endocrinol. Metab. 78(1), 20–24 (1994). doi:10.1210/jcem.78.1.7904613 PubMedGoogle Scholar
  20. 20.
    D.J. Torpy, C.C. Chen, N. Mullen, J.L. Doppman, J.A. Carrasquillo, G.P. Chrousos, L.K. Nieman, Lack of utility of (111)In-pentetreotide scintigraphy in localizing ectopic ACTH producing tumors: follow-up of 18 patients. J. Clin. Endocrinol. Metab. 84(4), 1186–1192 (1999). doi:10.1210/jcem.84.4.5576 CrossRefPubMedGoogle Scholar
  21. 21.
    A. Tabarin, N. Valli, P. Chanson, Y. Bachelot, V. Rohmer, V. Bex-Bachellerie, B. Catargi, P. Roger, F. Laurent, Usefulness of somatostatin receptor scintigraphy in patients with occult ectopic adrenocorticotropin syndrome. J. Clin. Endocrinol. Metab. 84(4), 1193–1202 (1999). doi:10.1210/jcem.84.4.5583 CrossRefPubMedGoogle Scholar
  22. 22.
    M. Yaneva, S. Vandeva, S. Zacharieva, A.F. Daly, A. Beckers, Genetics of Cushing’s syndrome. Neuroendocrinology 92(Suppl 1), 6–10 (2010). doi:10.1159/000314215 CrossRefPubMedGoogle Scholar
  23. 23.
    Y. de Keyzer, F. Lenne, C. Auzan, S. Jegou, P. Rene, H. Vaudry, J.M. Kuhn, J.P. Luton, E. Clauser, X. Bertagna, The pituitary V3 vasopressin receptor and the corticotroph phenotype in ectopic ACTH syndrome. J. Clin. Investig. 97(5), 1311–1318 (1996). doi:10.1172/jci118547 PubMedCentralCrossRefPubMedGoogle Scholar
  24. 24.
    Y. Tani, T. Sugiyama, H. Izumiyama, T. Yoshimoto, S. Yamada, Y. Hirata, Differential gene expression profiles of POMC-related enzymes, transcription factors and receptors between non-pituitary and pituitary ACTH-secreting tumors. Endocr. J. 58(4), 297–303 (2011)CrossRefPubMedGoogle Scholar
  25. 25.
    R.X. Liu, W.Q. Wang, L. Ye, Y.F. Bi, H. Fang, B. Cui, W.W. Zhou, M. Dai, J. Zhang, X.Y. Li, G. Ning, p21-activated kinase 3 is overexpressed in thymic neuroendocrine tumors (carcinoids) with ectopic ACTH syndrome and participates in cell migration. Endocrine 38(1), 38–47 (2010). doi:10.1007/s12020-010-9324-6 CrossRefPubMedGoogle Scholar
  26. 26.
    K. Pacak, I. Ilias, C.C. Chen, J.A. Carrasquillo, M. Whatley, L.K. Nieman, The role of [(18)F]fluorodeoxyglucose positron emission tomography and [(111)In]-diethylenetriaminepentaacetate-D-Phe-pentetreotide scintigraphy in the localization of ectopic adrenocorticotropin-secreting tumors causing Cushing’s syndrome. J. Clin. Endocrinol. Metab. 89(5), 2214–2221 (2004). doi:10.1210/jc.2003-031812 CrossRefPubMedGoogle Scholar
  27. 27.
    A.S. Karageorgiadis, G.Z. Papadakis, J. Biro, M.F. Keil, C. Lyssikatos, M.M. Quezado, M. Merino, D.S. Schrump, E. Kebebew, N.J. Patronas, M.K. Hunter, M.R. Alwazeer, L.P. Karaviti, A.E. Balazs, M.B. Lodish, C.A. Stratakis, Ectopic adrenocorticotropic hormone and corticotropin-releasing hormone co-secreting tumors in children and adolescents causing Cushing syndrome: a diagnostic dilemma and how to solve it. J. Clin. Endocrinol. Metab. 100(1), 141–148 (2015). doi:10.1210/jc.2014-2945 CrossRefPubMedGoogle Scholar
  28. 28.
    B. Venkitaraman, S. Karunanithi, A. Kumar, C. Bal, A.C. Ammini, R. Kumar, (6)(8)Ga-DOTATOC PET-CT in the localization of source of ectopic ACTH in patients with ectopic ACTH-dependent Cushing’s syndrome. Clin. Imaging 38(2), 208–211 (2014). doi:10.1016/j.clinimag.2013.10.007 CrossRefPubMedGoogle Scholar
  29. 29.
    L. Gilardi, M. Colandrea, S.L. Fracassi, M. Sansovini, G. Paganelli, (68) Ga- DOTA(0) -Tyr(3) octreotide (DOTATOC) positron emission tomography (PET)/CT in five cases of ectopic adrenocorticotropin-secreting tumours. Clin. Endocrinol. 81(1), 152–153 (2014). doi:10.1111/cen.12313 CrossRefGoogle Scholar
  30. 30.
    H.R. Kakade, R. Kasaliwal, V.S. Jagtap, A. Bukan, S.R. Budyal, S. Khare, A.R. Lila, T. Bandgar, P.S. Menon, N.S. Shah, Ectopic ACTH-secreting syndrome: a single-center experience. Endocr. Pract. 19(6), 1007–1014 (2013). doi:10.4158/ep13171.or CrossRefPubMedGoogle Scholar
  31. 31.
    Z.G. Ozkan, S. Kuyumcu, D. Balkose, B. Ozkan, N. Aksakal, E. Yilmaz, Y. Sanli, C. Turkmen, F. Aral, I. Adalet, The value of somatostatin receptor imaging with In-111 Octreotide and/or Ga-68 DOTATATE in localizing Ectopic ACTH producing tumors. Mol Imaging Radionucl. Ther 22(2), 49–55 (2013). doi:10.4274/Mirt.69775 PubMedCentralCrossRefPubMedGoogle Scholar
  32. 32.
    J. Wahlberg, B. Ekman, Atypical or typical adrenocorticotropic hormone-producing pulmonary carcinoids and the usefulness of 11C-5-hydroxytryptophan positron emission tomography: two case reports. J. Med. Case Rep. 7, 80 (2013). doi:10.1186/1752-1947-7-80 PubMedCentralCrossRefPubMedGoogle Scholar
  33. 33.
    M. Doi, T. Sugiyama, H. Izumiyama, T. Yoshimoto, Y. Hirata, Clinical features and management of ectopic ACTH syndrome at a single institute in Japan. Endocr. J. 57(12), 1061–1069 (2010)CrossRefPubMedGoogle Scholar
  34. 34.
    M.S. Zemskova, B. Gundabolu, N. Sinaii, C.C. Chen, J.A. Carrasquillo, M. Whatley, I. Chowdhury, A.M. Gharib, L.K. Nieman, Utility of various functional and anatomic imaging modalities for detection of ectopic adrenocorticotropin-secreting tumors. J. Clin. Endocrinol. Metab. 95(3), 1207–1219 (2010). doi:10.1210/jc.2009-2282 PubMedCentralCrossRefPubMedGoogle Scholar
  35. 35.
    A.B. Moraes, G.F. Taboada, M.P. Carneiro, L.V. Neto, L.E. Wildemberg, K. Madi, R.C. Domingues, M.R. Gadelha, Utility of [(18)F] fluoro-2-deoxy-D: -glucose positron emission tomography in the localization of ectopic ACTH-secreting tumors. Pituitary 12(4), 380–383 (2009). doi:10.1007/s11102-008-0125-3 CrossRefPubMedGoogle Scholar
  36. 36.
    H. Xu, M. Zhang, G. Zhai, M. Zhang, G. Ning, B. Li, The role of integrated (18)F-FDG PET/CT in identification of ectopic ACTH secretion tumors. Endocrine 36(3), 385–391 (2009). doi:10.1007/s12020-009-9247-2 CrossRefPubMedGoogle Scholar
  37. 37.
    J. Kumar, M. Spring, P.V. Carroll, S.F. Barrington, J.K. Powrie, 18Flurodeoxyglucose positron emission tomography in the localization of ectopic ACTH-secreting neuroendocrine tumours. Clin. Endocrinol. 64(4), 371–374 (2006). doi:10.1111/j.1365-2265.2006.02471.x Google Scholar
  38. 38.
    A. Meftah, A. Moumen, EL. Massine, M. Hammoumi, S. Hajhouji, S., E.L.H. Jadi, A. Anas Guerboub, S. Elmoussaoui, H. Mayaudon, E. Hassane Kabiri, K. Hakkou, G. Belmejdoub, Paraneoplastic Cushing’s syndrome, a real diagnostic and therapeutic challenge: a case report and literature review. La Revue de medecine interne/fondee… par la Societe nationale francaise de medecine interne (2015). doi:10.1016/j.revmed.2014.12.008
  39. 39.
    A. Markou, P. Manning, B. Kaya, S.N. Datta, J.B. Bomanji, G.S. Conway, [18F]fluoro-2-deoxy-d-glucose ([18F]FDG) positron emission tomography imaging of thymic carcinoid tumor presenting with recurrent Cushing’s syndrome. Eur. J. Endocrinol/Eur. Fed. Endocr. Soc. 152(4), 521–525 (2005). doi:10.1530/eje.1.01839 CrossRefGoogle Scholar
  40. 40.
    T.A. Jackson, K.W. Choong, J.A. Eng, D. McAneny, R.M. Subramaniam, P.E. Knapp, F-18 FDG PET/CT imaging of endogenous Cushing syndrome. Clin. Nucl. Med. 36(12), e231–e232 (2011). doi:10.1097/RLU.0b013e3182336360 CrossRefPubMedGoogle Scholar
  41. 41.
    S.M. Deng, W. Zhang, B. Zhang, Y.Y. Chen, J.H. Li, Y.W. Wu, Correlation between the uptake of 18F-fluorodeoxyglucose (18F-FDG) and the expression of proliferation-associated antigen Ki-67 in cancer patients: a meta-analysis. PLoS One 10(6), e0129028 (2015). doi:10.1371/journal.pone.0129028 PubMedCentralCrossRefPubMedGoogle Scholar
  42. 42.
    G. Treglia, E. Salomone, G. Petrone, A. Giaccari, G. Rindi, V. Rufini, A rare case of ectopic adrenocorticotropic hormone syndrome caused by a metastatic neuroendocrine tumor of the pancreas detected by 68 Ga-DOTANOC and 18F-FDG PET/CT. Clin. Nucl. Med. 38(7), e306–e308 (2013). doi:10.1097/RLU.0b013e318279ec68 CrossRefPubMedGoogle Scholar
  43. 43.
    S. Dubois, O. Morel, P. Rodien, F. Illouz, S. Girault, A. Cahouet, F. Lacoeuille, M. Brousseau, J. Picquet, V. Rohmer, A Pulmonary adrenocorticotropin-secreting carcinoid tumor localized by 6-Fluoro-[18F]L-dihydroxyphenylalanine positron emission/computed tomography imaging in a patient with Cushing’s syndrome. J. Clin Endocrinol. Metab. 92(12), 4512–4513 (2007). doi:10.1210/jc.2007-1337 CrossRefPubMedGoogle Scholar
  44. 44.
    C. Schalin-Jantti, A. Ahonen, M. Seppanen, 18F-DOPA PET/CT but not 68 Ga-DOTA-TOC PET/CT revealed the underlying cause of ectopic Cushing syndrome. Clin. Nucl. Med. 37(9), 904–905 (2012). doi:10.1097/RLU.0b013e318262adc7 CrossRefPubMedGoogle Scholar
  45. 45.
    P. Chittiboina, B.K. Montgomery, C. Millo, P. Herscovitch, R.R. Lonser, High-resolution(18)F-fluorodeoxyglucose positron emission tomography and magnetic resonance imaging for pituitary adenoma detection in Cushing disease. J. Neurosurg. 122(4), 791–797 (2015). doi:10.3171/2014.10.jns14911 CrossRefPubMedGoogle Scholar
  46. 46.
    R.A. Feelders, L.J. Hofland, W.W. de Herder, Medical treatment of Cushing’s syndrome: adrenal-blocking drugs and ketaconazole. Neuroendocrinology 92(Suppl 1), 111–115 (2010). doi:10.1159/000314292 CrossRefPubMedGoogle Scholar
  47. 47.
    J. Heyn, C. Geiger, C.L. Hinske, J. Briegel, F. Weis, Medical suppression of hypercortisolemia in Cushing’s syndrome with particular consideration of etomidate. Pituitary 15(2), 117–125 (2012). doi:10.1007/s11102-011-0314-3 CrossRefPubMedGoogle Scholar
  48. 48.
    K. Ritzel, F. Beuschlein, A. Mickisch, A. Osswald, H.J. Schneider, J. Schopohl, M. Reincke, Clinical review: outcome of bilateral adrenalectomy in Cushing’s syndrome: a systematic review. J. Clin. Endocrinol. Metab. 98(10), 3939–3948 (2013). doi:10.1210/jc.2013-1470 CrossRefPubMedGoogle Scholar
  49. 49.
    C. Bluemel, C. Lapa, A. Mottok, S. Hahner, K. Herrmann, Tumor localization in ectopic Cushing syndrome using combined PET/CT imaging. Clin. Nucl. Med. 38(9), 749–751 (2013). doi:10.1097/RLU.0b013e31829962d3 CrossRefPubMedGoogle Scholar
  50. 50.
    S.M. Corsello, P. Senes, R. Iezzi, V. Rufini, M.T. Congedo, R.M. Paragliola, A. Pontecorvi, Cushing’s syndrome due to a bronchial ACTH-secreting carcinoid successfully treated with radiofrequency ablation (RFA). J. Clin. Endocrinol. Metab. 99(5), E862–E865 (2014). doi:10.1210/jc.2013-4359 CrossRefPubMedGoogle Scholar
  51. 51.
    V. Cuccurullo, G.L. Cascini, O. Tamburrini, L. Mansi, A. Rotondo, Less frequent requests for In-111 pentreotide and its brothers of endocrinological interest. Minerva Endocrinol. 36(1), 41–52 (2011)PubMedGoogle Scholar
  52. 52.
    N. Sauer, C.S. Zur Wiesch, J. Flitsch, W. Saeger, S. Klutmann, J. Zustin, A. Luebke, J. Aberle, Cushing’s syndrome due to a corticotropin-releasing hormone- and adrenocorticotrophic hormone-producing neuroendocrine pancreatic tumor. Endocr. Pract. 20(4), e53–57 (2014). doi:10.4158/ep13001.cr
  53. 53.
    M.V. Davi, M. Salgarello, G. Francia, Positive (68)Ga-DOTATOC-PET/CT after cortisol level control during ketoconazole treatment in a patient with liver metastases from a pancreatic neuroendocrine tumor and ectopic Cushing syndrome. Endocrine 49(2), 566–567 (2015). doi:10.1007/s12020-014-0391-y CrossRefPubMedGoogle Scholar
  54. 54.
    O.D. Bruno, K. Danilowicz, M. Manavela, D. Mana, M.A. Rossi, Long-term management with octreotide or cabergoline in ectopic corticotropin hypersecretion: case report and literature review. Endocr. Pract. 16(5), 829–834 (2010). doi:10.4158/ep09286.cr CrossRefPubMedGoogle Scholar
  55. 55.
    S.L. Barbosa, P. Rodien, S. Leboulleux, P. Niccoli-Sire, J.L. Kraimps, P. Caron, F. Archambeaud-Mouveroux, B. Conte-Devolx, V. Rohmer, Ectopic adrenocorticotropic hormone-syndrome in medullary carcinoma of the thyroid: a retrospective analysis and review of the literature. Thyroid 15(6), 618–623 (2005). doi:10.1089/thy.2005.15.618 CrossRefPubMedGoogle Scholar
  56. 56.
    K. Oberg, Molecular imaging radiotherapy: theranostics for personalized patient management of neuroendocrine tumors (NETs). Theranostics 2(5), 448–458 (2012). doi:10.7150/thno.3931 PubMedCentralCrossRefPubMedGoogle Scholar
  57. 57.
    G. Treglia, L. Giovanella, F. Lococo, Evolving role of PET/CT with different tracers in the evaluation of pulmonary neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging 41(5), 853–855 (2014). doi:10.1007/s00259-014-2695-9 CrossRefPubMedGoogle Scholar
  58. 58.
    G. Treglia, P. Castaldi, G. Rindi, A. Giordano, V. Rufini, Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine 42(1), 80–87 (2012). doi:10.1007/s12020-012-9631-1 CrossRefPubMedGoogle Scholar
  59. 59.
    E. Panagiotidis, J. Bomanji, Role of 18F-fluorodeoxyglucose PET in the study of neuroendocrine tumors. PET Clin. 9(1), 43–55 (2014). doi:10.1016/j.cpet.2013.08.008 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Prasanna Santhanam
    • 1
  • David Taieb
    • 2
    • 3
  • Luca Giovanella
    • 4
  • Giorgio Treglia
    • 4
  1. 1.Section of Endocrinology, Department of Internal Medicine, Joan C Edwards School of MedicineMarshall UniversityHuntingtonUSA
  2. 2.Department of Nuclear Medicine, La Timone University Hospital, CERIMEDAix-Marseille UniversityMarseilleFrance
  3. 3.Marseille Cancerology Research CenterInstitut Paoli-CalmettesMarseilleFrance
  4. 4.Nuclear Medicine and PET/CT CenterOncology Institute of Southern SwitzerlandBellinzona and LuganoSwitzerland

Personalised recommendations